Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ: ALZN )

1.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,719
Open 1.120
Bid (Size) 1.130 (1)
Ask (Size) 1.190 (1)
Prev. Close 1.140
Today's Range 1.120 - 1.160
52wk Range 1.060 - 15.06
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alzamend Neuro to Present at the Sequire Investor Summit
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects. 
Via Benzinga

Performance

YTD
-5.00%
-5.00%
1 Month
-10.24%
-10.24%
3 Month
-30.49%
-30.49%
6 Month
-50.22%
-50.22%
1 Year
-86.88%
-86.88%

More News

Read More
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Via PressReach
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
Via Benzinga
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Via PressReach
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Via PressReach
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
From Alzamend Neuro, Inc.
Via Business Wire
Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
From Alzamend Neuro, Inc.
Via Business Wire
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
Via Benzinga
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
From Alzamend Neuro, Inc.
Via Business Wire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Alzamend Neuro Issues Letter to Stockholders
From Alzamend Neuro
Via Business Wire
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Via PressReach
Exposures Product Safety
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
Via Benzinga
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
Via PressReach
Exposures Product Safety
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
Via PressReach
Exposures Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.